Welcome to our dedicated page for West Pharm Svcs news (Ticker: WST), a resource for investors and traders seeking the latest updates and insights on West Pharm Svcs stock.
West Pharmaceutical Services, Inc. (NYSE: WST) provides injectable drug administration solutions and services for pharmaceutical, biotechnology and generic drug customers. Its business includes elastomer-based packaging components such as stoppers, seals and plungers, nonglass containment technologies, auto-injectors and contract services for device manufacturing, assembly, packaging, validation, analytical testing and regulatory support.
News about West commonly covers quarterly results, revenue guidance, Proprietary Products and Contract Manufacturing performance, capacity additions for high-volume injectable therapies, and demand tied to biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. Other recurring developments include dividends, share repurchase authorizations, investor conference participation and governance or executive-transition updates.
Summary not available.
Summary not available.
West Pharmaceutical Services (NYSE: WST) reported its Q1 2023 financial results on April 27, 2023. Net sales were $716.6 million, down 0.5% year-over-year, but organic sales increased by 2.3%. The diluted EPS dropped to $1.85, a decline of 19.2%. The company has raised its full-year net sales guidance to $2.965 billion to $2.990 billion, and adjusted-diluted EPS guidance to $7.50 to $7.65. A dividend of $0.19 per share was approved for Q3 2023, payable on August 2, 2023, to shareholders of record by July 26, 2023. Operational cash flow stood at $138.1 million, reflecting an 8.7% decrease, while free cash flow dropped 34.4% to $56.0 million. The firm anticipates continued growth despite a decline in COVID-19 related sales affecting its Biologics market unit.
West Pharmaceutical Services, a global leader in injectable solutions, announced the release date for its first-quarter 2023 financial results. The results will be published before the market opens on April 27, 2023. A conference call to discuss these results and future business expectations will be held at 9:00 a.m. Eastern Time on the same day. Investors can access a live audio-only webcast on the company’s Investor Relations website. To participate in the call, interested parties need to register in advance to receive dial-in details. A slide presentation will accompany the call and be available on the company's website. West Pharmaceutical reported $2.89 billion in net sales for 2022, marking its 100-year anniversary of innovation in healthcare.
West Pharmaceutical Services, Inc. (NYSE: WST) has announced a quarterly dividend of $0.19 per share, payable on May 3, 2023, to shareholders recorded as of April 26, 2023. This dividend reflects the company's ongoing commitment to returning value to its shareholders. In fiscal year 2022, West generated $2.89 billion in net sales, marking a significant milestone in its 100-year history of innovation in the injectable solutions market. The company supports pharmaceutical developers with reliable containment and delivery solutions, underscoring its critical role in healthcare.
West Pharmaceutical Services, Inc. (NYSE: WST) reported its fourth-quarter and full-year 2022 results, indicating a 3.0% decline in Q4 net sales to $708.7 million, with organic growth of 2.6%. Full-year 2022 net sales reached $2.887 billion, growing by 2.0% with 7.7% organic growth. Reported diluted EPS for Q4 was $1.36, dropping 29.5%, while full-year diluted EPS decreased 10.8% to $7.73. For 2023, the company expects net sales between $2.935 billion and $2.960 billion, with adjusted diluted EPS guidance of $7.25 to $7.40. A $1 billion share repurchase program was approved, with a focus on HVP manufacturing capacity to meet growing demand.
West Pharmaceutical Services (NYSE: WST) announced the expansion of its collaboration with Corning Incorporated, granting exclusive distribution rights for Corning Valor® Glass vials. The first product, West Ready Pack™ with Corning Valor® RTU Vials, uses SG EZ-fill® technology and aims to improve the packaging and delivery of injectable drugs. This collaboration, which includes a multimillion-dollar investment started in January 2022, focuses on enhancing patient safety and expanding access to healthcare. The combined system boasts benefits like proven container closure integrity and a sterile, ready-to-use design.
West Pharmaceutical Services (NYSE: WST) will release its fourth-quarter and full-year 2022 financial results on February 16, 2023, before market opening. A conference call to discuss these results will follow at 9:00 a.m. Eastern Time. Investors can access the live audio-only webcast via the Company’s Investor Relations website and participate by registering in advance. West will also attend the Barclays Global Healthcare Conference in Miami on March 14, 2023, and the KeyBanc Life Sciences & MedTech Investor Forum virtually on March 22, 2023. West, celebrating 100 years of innovation, generated $2.83 billion in net sales in FY 2021.
West Pharmaceutical Services (NYSE: WST) announced its participation at Pharmapack Europe 2023, showcasing innovations in injectable drug packaging. The company introduced three new products: West Ready Pack™ with Corning Valor® RTU Vials, Daikyo Crystal Zenith® 2.25mL Insert Needle Syringe System, and FluroTec® 5-10mL Cartridge Plunger. These innovations aim to address the demands of complex drug delivery and enhance patient safety. Additionally, West's presentations include discussions on market trends and innovations in drug delivery systems, highlighting the company's ongoing commitment to improving patient adherence and pharmaceutical solutions.
West Pharmaceutical Services, Inc. (NYSE: WST), a leader in injectable drug solutions, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 12, 2023, at 9:00 am PST. A live audio webcast will be available on the company's website, with a replay accessible for 90 days. With nearly 10,000 employees across 50 sites, West generated $2.83 billion in net sales in 2021, providing crucial containment and delivery services for medicines worldwide. For more insights, visit www.westpharma.com.